Modality
Gene Editing
MOA
MALT1i
Target
CDK2
Pathway
mTOR
CLLWMEwing Sarcoma
Development Pipeline
Preclinical
Feb 2017
→ Feb 2031
PreclinicalCurrent
NCT04517721
2,339 pts·WM
2017-02→2031-02·Completed
NCT08424182
2,101 pts·CLL
2024-11→2025-04·Completed
4,440 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2311mo agoInterim· CLL
2031-02-114.9y awayInterim· WM
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2025-04-23 · 11mo ago
CLL
Interim
2031-02-11 · 4.9y away
WM
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04517721 | Preclinical | WM | Completed | 2339 | Mayo |
| NCT08424182 | Preclinical | CLL | Completed | 2101 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |